Vaccine therapy for P. acnes-associated diseases

Area of Science:

• Microbiology
• Immunology
• Vaccinology

Background:

• Propionibacterium acnes (P. acnes) is implicated in acne vulgaris and various other infections, including endocarditis and biomaterial contamination.
• Antibiotic therapies are the primary treatment for P. acnes-associated diseases, while vaccine development remains less explored.
• P. acnes exhibits significant pathogenicity across a spectrum of clinical conditions.

Purpose of the Study:

• To develop and evaluate novel vaccine strategies against P. acnes-associated diseases.
• To investigate the efficacy of P. acnes whole-cell and sialidase-based vaccines in conferring protective immunity.

Main Methods:

• Development of vaccines using a cell wall-anchored sialidase of P. acnes or killed whole P. acnes organisms.
• Immunization of ICR mice with the developed vaccines.
• Assessment of in vivo protective immunity against P. acnes challenge.
• Measurement of P. acnes-induced cytokine production levels.

Main Results:

• Vaccination with killed P. acnes or P. acnes sialidase induced protective immunity in mice against P. acnes challenge.
• Immunized mice exhibited decreased elevation of cytokine production in response to P. acnes.
• The vaccines demonstrated potential in mitigating P. acnes-associated inflammatory responses.

Conclusions:

• Killed P. acnes and sialidase-based vaccines represent a promising therapeutic approach for P. acnes-associated diseases.
• These vaccines offer a potential alternative to conventional antibiotic treatments.
• Further research into P. acnes vaccines could lead to novel strategies for managing P. acnes infections.